VEGFbased

VEGFbased refers to approaches that exploit vascular endothelial growth factor (VEGF) signaling to influence angiogenesis. VEGF proteins stimulate the growth and permeability of blood vessels and play key roles in development, wound healing, and pathological neovascularization.

VEGF-A is the principal ligand in most angiogenic processes, acting mainly through receptors VEGFR-1 and VEGFR-2 to promote endothelial proliferation, migration, and vessel formation. Other VEGF family members regulate lymphangiogenesis and vessel remodeling in specific contexts.

Therapeutic uses of VEGF-based strategies span pro-angiogenic and anti-angiogenic aims. Pro-angiogenic approaches deliver VEGF protein, gene therapy, or controlled-release systems to enhance perfusion in ischemic tissue and promote wound healing. Anti-VEGF therapies, including monoclonal antibodies and fusion proteins such as bevacizumab and aflibercept, inhibit VEGF signaling to slow tumor growth or treat ocular neovascular diseases.

Delivery methods include protein injections, gene delivery, and biomaterial systems; safety considerations include dose control and risks of edema or aberrant vessel growth. Anti-VEGF therapies can cause hypertension, thromboembolism, or retinal toxicity with long-term use, and regulatory approval is indication-specific.

Ongoing research seeks more precise targeting and safer delivery to unlock broader regenerative and disease-modifying potential while minimizing adverse effects.